- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04684979
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-compatible Related or Unrelated Donors in Patients With B-Cell Lymphoid Malignancies
Study Overview
Status
Detailed Description
This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLBCLC) and mantle cell non-Hodgkin's lymphoma (MCL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL). The study design will be based on a total of 90 patients, 30 recipients of related matched and 60 recipients of mismatched related or unrelated PBSCT.
It is anticipated that the accrual will last 5-6 years. At the conclusion of the study, the safety and a preliminary assessment of efficacy of NMA PBSCT will be determined. The treatment will be declared efficacious if the disease-free survival at 1 year in this patient population is at least 50%.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33176
- Miami Cancer Institute at Baptist Health of South Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
:
- Patients aged 18-74 years at initial referral with a suitably matched related or unrelated donor who have provided their informed consent to participate in the clinical trial.
- If post-pubertal, females agree to take hormonal therapy to suppress menses unless a specific contra-indication to estrogen exists
Diagnosis:
- Patients with CD20+ aggressive B cell NHL (DLBCL, large cell transformation of indolent NHL/CLL, or mantle cell) OR CD20+ indolent NHL/CLL. Relapsed disease must be biopsy proven and CD20 positivity must be demonstrated within the 12 months prior to protocol enrollment.
Eligible patients with DLBCL NHL will:
- have relapsed disease following initial therapy but failed to mobilize or had bone marrow involvement and therefore are not suitable for an autologous transplant OR
- have high-intermediate or high-risk second-line age-adjusted International Prognostic Index score and be in 2nd CR/PR following an autologous transplant OR
- have failed an autologous transplant and be in PR or better after salvage chemotherapy.
Eligible patients with transformed indolent NHL/CLL will:
• have CR/PR of the large cell component of their disease after either salvage chemotherapy or an autologous transplant.
Eligible patients with mantle cell NHL will:
- be high-risk such as p53 positivity and be in 1st CR/PR after initial therapy OR
- have relapsed disease following initial therapy and be in 2nd or 3rd CR/PR after salvage chemotherapy.
Eligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) or CLL will:
• have 1st or subsequent progression or primary refractory disease (pre-allograft cytoreduction necessary but CR/PR not required).
Pre-allograft Salvage Chemotherapy:
- This can include a single autologous transplant using high dose chemotherapy conditioning if appropriate OR ≥ 2 cycles of intensive combination chemotherapy (e.g. RICE) as appropriate according to diagnosis and prior therapy.
- CLL patients who have received CAMPATH do not have to receive pre-allograft salvage chemotherapy.
Timing of PBSCT:
• Admission for PBSCT must be within 120 days of autologous transplantation OR 80 days of the last cycle of chemotherapy.
Organ Function and Performance Status Criteria:
- Karnofsky score ≥ 70 %
- calculated creatinine clearance ≥ 50 mL/min OR if creatinine ≥ 1.2, a history of renal dysfunction, age > 50 years, prior transplant, and/or a single kidney, the patient must have a measured creatinine clearance (using 24 hour urine collection) ≥ 50 mL/min
- bilirubin < 2.5, AST/ALT ≤ 3 x upper limit of normal (unless benign congenital hyperbilirubinemia)
- pulmonary function (spirometry and corrected DLCO) ≥ 50% normal
- left ventricular ejection fraction ≥ 40%
- albumin ≥ 2.5. Donor HLA-compatible related donors
- Patients who have an HLA-matched or one allele mismatched related donor are eligible for entry on this protocol. This will include a healthy related donor who is genotypically or phenotypically matched at least 9/10 of the A, B, C, DRB1, and DQB1 loci, as tested by high resolution.
HLA-compatible Unrelated donors • Patients who do not have a related HLA-matched donor but have an unrelated donor who is matched at
≥ 9/10 (allele mismatch only) of the A, B, C, DRB1, and DQB1 loci, as tested by high resolution.
Exclusion Criteria:
Diagnosis: known negativity for CD20 pre-allograft; mantle cell or DLBCL NHL with progressive disease at allograft work-up
- Prior Therapy: prior allogeneic transplant (prior autologous transplant is acceptable)
- Cytoreduction and timing of NMA PBSCT: patients unable to complete planned cytoreduction due to therapy complications, or who undergo cytoreduction but are unable to proceed to allografting within the defined time period, are ineligible for allograft on protocol
- Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or HIV infection
- Patients positive for Hepatitis B or C at risk for viral reactivation.
- Inadequate performance status/organ function
- Pregnant or breast feeding
- Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HLA-compatible Related Donor
This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies.
Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
|
NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
|
Experimental: Unrelated Donor
This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies.
Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
|
NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimate the overall and event-free survival
Time Frame: 1 year
|
The primary aim of this study is to obtain a preliminary estimate of the overall and event-free survival at 1 year after NMA PBSCT with peri-transplant rituximab using an HLA matched or single HLA allele disparate related or unrelated donors
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Speed of Recovery Post Allograft
Time Frame: 100 days
|
the speed of neutrophil and platelet recovery post allograft
|
100 days
|
Response to Engraftment
Time Frame: 100 days
|
the incidence and speed of donor-derived engraftment
|
100 days
|
Status of Graft Versus Host Disease
Time Frame: 100 days
|
The incidence and severity of acute GVHD(Graft Versus Host Disease) at 100 days
|
100 days
|
Number of Participants with Graft Versus Host Disease
Time Frame: 1 year
|
The incidence and severity of chronic GVHD (Graft Versus Host Disease) at 1 year
|
1 year
|
Number of Participants with Complications
Time Frame: 100 days
|
the incidence of serious infectious complications with their correlation with laboratory measurements of immune recovery
|
100 days
|
Response Rate to Vaccination
Time Frame: 100 days
|
the response to vaccination after PBSCT (Peripheral Blood Stem Cells Transplantation)
|
100 days
|
Number of Transplant Related Mortality Incidences
Time Frame: 100 and 180 days
|
the incidence of Transplant Related Mortality at 100 and 180 days
|
100 and 180 days
|
Number of Relapse or Disease Progression Instances
Time Frame: 1 and 2 years
|
the incidence of malignant relapse or disease progression at 1 and 2 years
|
1 and 2 years
|
Number of Overall and Event Free Survival
Time Frame: 2 years
|
the probabilities of overall and event-free survival at 2 years after Peripheral Blood Stem Cells Transplantation
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Guenther Koehne, MD, PhD, Miami Cancer Institute at Baptist Health of South Florida
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-KOE-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin Lymphoma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Acerta Pharma BVAstraZenecaActive, not recruitingNon Hodgkin LymphomaUnited States, Canada, Italy
Clinical Trials on Hematopoietic Stem Cells from HLA-compatible Related
-
Hannover Medical SchoolCompletedAcute Myeloid Leukemia (AML)Austria, Czechia, Germany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedKidney CancerUnited States
-
Tehran University of Medical SciencesHormozgan University of Medical SciencesUnknownCerebral Palsy, SpasticIran, Islamic Republic of
-
Michio Hirano, MDNational Institute of Neurological Disorders and Stroke (NINDS); Cornell UniversityWithdrawnMitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
-
Institut Paoli-CalmettesUnknownMultiple Myeloma | Non Hodgkin Lymphoma | Acute LeukemiaFrance
-
Smart Immune SASRecruitingHealthy VolunteersFrance
-
Shenzhen HemogenRecruiting
-
Shenzhen HemogenRecruiting
-
Bioray LaboratoriesFirst Affiliated Hospital of Guangxi Medical UniversitySuspendedThalassemia MajorChina
-
Bioray LaboratoriesXiangya Hospital of Central South University; The 923rd Hospital of Joint Logistics...Completedβ Thalassemia MajorChina